Loading
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Regular session
$2.14
+$0.08 · +3.88%
Regular session · ET · Market data may be delayed.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Day range
Current $2.14
52-week range
Current $2.14
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
41
Fair Value
Sentiment
49
Mixed
Risk
73
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Day range
Current $2.14
52-week range
Current $2.14
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 319.71K USD | 8.01M USD | 8.68M USD | 11.24M USD | 13.6M USD |
| Cost of goods sold | 112.93K USD | 2.95M USD | 3.13M USD | 4.44M USD | 5.25M USD |
| Gross profit | 206.79K USD | 5.06M USD | 5.55M USD | 6.8M USD | 8.35M USD |
| Research and development | 588.26K USD | 1.8M USD | 2.32M USD | 2.54M USD | 2.37M USD |
| Selling, general, and administrative | 2.37M USD | 9.92M USD | 17.87M USD | 31.34M USD | 33.21M USD |
| Operating expenses | 2.95M USD | 12.79M USD | 20.19M USD | 33.88M USD | 66.23M USD |
| Interest income | — | 14K USD | 26K USD | — | — |
| Interest expense | 146.64K USD | — | — | 113K USD | 832K USD |
| Depreciation and amortization | 11.99K USD | 22K USD | 154K USD | 2.15M USD | 1.97M USD |
| Operating income | −2.75M USD | −7.73M USD | −14.64M USD | −27.08M USD | −57.88M USD |
| Net income | −10.26M USD | −7.13M USD | −11.39M USD | −46.21M USD | −63.15M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.50
63.55% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 15, 2025 | 1:4 | — | — |
Stock split | May 9, 2025 | 1:25 | — | — |
Stock split | Sep 23, 2024 | 1:58 | — | — |
Stock split | Dec 23, 2022 | 1:50 | — | — |
Stock split | Jun 16, 2021 | 1:3 | — | — |
Stock split | Nov 12, 2019 | 1:120 | — | — |
Effective Aug 15, 2025
1:4
Effective May 9, 2025
1:25
Effective Sep 23, 2024
1:58
Effective Dec 23, 2022
1:50
Effective Jun 16, 2021
1:3
Effective Nov 12, 2019
1:120
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
